These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16161751)

  • 1. [Surveillance of antimicrobial resistance of Streptococcus pneumoniae isolates from the Kinki Region of Japan during 2003/2004. The Surveillance Program of Bacterial Resistance in the Kinki Region of Japan; SBRK].
    Satoh K; Sueyoshi N; Komatsu M; Shimakawa K; Toyokawa M; Nishi I; Nishio H; Sakamoto M; Yamashita T; Okamoto K; Nakamura T; Nomura C; Wada Y; Ono T; Orita T; Kinoshita S; Koufuku T
    Jpn J Antibiot; 2005 Jun; 58(3):221-30. PubMed ID: 16161751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
    Ishigo S; Tamaya T; Matsubara S; Suematsu H; Sawamura H; Matsukawa Y; Hashido H; Iwata I; Mikamo H
    Jpn J Antibiot; 2000 Dec; 53(12):652-9. PubMed ID: 11234221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Castanheira M; Gales AC; Pignatari AC; Jones RN; Sader HS
    Microb Drug Resist; 2006; 12(2):91-8. PubMed ID: 16922623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2002). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Yamaguti O; Ishibashi K; Shigeta S; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Nishikawa M; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Takahashi K; Naito S; Egashira T; Kohno S; Miyazaki Y; Hirakata Y; Aoki S
    Jpn J Antibiot; 2004 Jun; 57(3):246-74. PubMed ID: 15376785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiological analysis of Streptococcus pneumoniae in Gifu prefecture].
    Matsukawa Y; Yamagishi Y; Mikamo H; Sawamura H; Matsubara S; Yamaoka K; Asano Y; Ishigo S; Suematsu H; Mutou T; Teraji M; Hashido H; Terada H; Saeki H; Miyabe T; Tanaka K; Watanabe K; Akita S; Okada M; Takemoto Y; Sakuma T
    Jpn J Antibiot; 2010 Jun; 63(3):224-41. PubMed ID: 20976879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae].
    Maekawa M; Fukuda Y; Sugiura Y; Kamiyama T; Futakuchi N; Takahata M; Mitsuyama J
    Jpn J Antibiot; 2003 Feb; 56(1):27-35. PubMed ID: 12723396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of sitafloxacin against clinical isolates in 2012].
    Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y
    Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)].
    Shimada K; Nakano K; Igari J; Oguri T; Ikemoto H; Mori T; Yokouchi H; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Okada S; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Nakata K; Nakatani T; Inagawa H; Kudo K; Kobayashi N; Tanaka T; Kobayashi H; Goto H; Kawai S; Takeda H; Sumitomo M; Matsushima T; Niki Y; Kohno S; Miyazaki Y; Yanagihara K; Hirakata Y; Matsuda J; Nasu M; Hiramatsu K; Suga M; Tosaka M
    Jpn J Antibiot; 2004 Jun; 57(3):213-45. PubMed ID: 15376784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Hirose T; Sato S; Shigeta S; Fujime M; Fujita K; Yamaguti O; Ishibashi K; Igari J; Suzutani T; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Furuya N; Murai M; Deguchi T; Ishihara S; Ooe H; Matsumoto T; Takahashi K; Nishikawa M; Naito S; Egashira T; Konishi T; Oka T; Kitamura M; Kohno S; Fukuhara Y; Hirakata Y; Kondo A; Matsuda J; Nakano M; Kamidono S; Suzuki Y; Arakawa S; Kumon H; Monden K
    Jpn J Antibiot; 2005 Dec; 58(6):518-43. PubMed ID: 16521344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
    Ishida T; Maniwa K; Kagioka H; Hirabayashi M; Onaru K; Tomioka H; Hayashi M; Tomii K; Gohma I; Ito Y; Hirai T; Ito I; Mishima M
    Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Takahashi H
    Jpn J Antibiot; 2004 Dec; 57(6):465-74. PubMed ID: 15747584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of sitafloxacin against clinical isolates in 2009].
    Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
    Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.
    Doern GV; Heilmann KP; Huynh HK; Rhomberg PR; Coffman SL; Brueggemann AB
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1721-9. PubMed ID: 11353617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Pseudomonas aeruginosa isolated in major hospitals in Nagano prefecture].
    Hachiya T; Kubo K; Yanagisawa H
    Jpn J Antibiot; 2004 Apr; 57(2):157-71. PubMed ID: 15219055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The change of susceptibility of Streptococcus pneumoniae strains isolated from pediatric patients at Asahikawa Kosei Hospital between 2011 and 2015.
    Sakata H
    Jpn J Antibiot; 2016 Dec; 69(6):367-372. PubMed ID: 30226931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.